Clinical Trials - March 23, 2026
BioArctic presents new data on long-term, real-world treatment with lecanemab
BioArctic’s partner Eisai presented the data at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders, held in Copenhagen, Denmark March 17-21.
Agreement - March 23, 2026
Mendus signs agreement with Olivia Newton-John Cancer Research Institute
Mendus has entered into an agreement with the Olivia Newton-John Cancer Research Institute (ONJCRI), an Australian cancer research institute, to support the DIVA trial with the company’s lead product vididencel in acute myeloid leukemia (AML).
In a new job - March 23, 2026
Lundbeck appoints Chief AI Officer
Markus Kede will join the Executive Leadership Team and report to President and CEO, Charl van Zyl.
Clinical Trials - March 20, 2026
Lundbeck advances Parkinson’s research with new Phase 1b data
The company has presented new data from a Phase 1b proof-of-mechanism trial of Lu AF28996, a novel compound invented by Lundbeck with dopamine D1/D2 receptor agonist activity.
Financing - March 19, 2026
Everdrone raises SEK 36 million
The recently completed funding round was led by the investment firm Sciety.
Biotech Business - March 19, 2026
FluoGuide receives FDA Fast Track Designation
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to FG001 as an intraoperative imaging agent to guide surgical resection of high-grade glioma.
